Robert DiCrisci | Source | CEO at NextSource Pharmaceuticals

This approval adds a fourth dosage strength to the Gleostine® product line-up that now includes 5, 10, 40, and 100 mg strengths, offering physicians a wider selection of dosage options to help best tailor medical treatments to the unique needs of each patient. This latest approval offers physicians more precise dosing options in treating patients afflicted with cancer. We believe that expanding our oncology product line will allow us to drive change in how cancer may be treated.